29021-98-5

Basic information

• Product Name: 4,4-(Ethylenebisoxy)-1-pentanol
• Synonyms: 2-Methyl-1,3-dioxolane-2-(1-propanol);4,4-(Ethylenebisoxy)-1-pentanol;3-(2-methyl-1,3-dioxolan-2-yl)propan-1-ol
• CAS NO: 29021-98-5
• Molecular Formula: C₇H₁₄O₃
• Molecular Weight: 146.18
• Mol File: 29021-98-5.mol
• Article Data: 18

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 4,4-(Ethylenebisoxy)-1-pentanol(CAS DataBase Reference)
• NIST Chemistry Reference: 4,4-(Ethylenebisoxy)-1-pentanol(29021-98-5)
• EPA Substance Registry System: 4,4-(Ethylenebisoxy)-1-pentanol(29021-98-5)

Safety Data

• Hazardous Substances Data: 29021-98-5(Hazardous Substances Data)

Usage

General Description

4,4-(Ethylenebisoxy)-1-pentanol is a chemical compound also known as E-446, which is commonly used as an emulsifier and stabilizer in various food and cosmetic products. It is a polyethylene glycol ether of 1-pentanol, and its main function is to improve the texture, consistency, and shelf life of the products it is used in. In the food industry, it is often found in ice cream, mayonnaise, and salad dressings, while in cosmetics, it is used in various creams, lotions, and shampoos. The European Food Safety Authority and the United States Food and Drug Administration have both approved its use, and it is generally considered safe for consumption and topical application in the recommended amounts.

Upstream product

• 20449-21-2 2-(but-3-en-1-yl)-2-methyl-1,3-dioxolane 
• 1576-85-8 4-pentenyl acetate 
• 92403-96-8 2-Methyl-2-(3-methylsulfanylmethoxy-propyl)-[1,3]dioxolane 
• 539-88-8 4-oxopentanoic acid ethyl ester 
• 821-09-0 n-Pent-4-enyl alcohol 
• 123-76-2 levulinic acid 
• 5185-97-7 4-oxopentyl acetate 
• 624-45-3 levulinic acid methyl ester 
• 35351-33-8 methyl 3‐(2‐methyl‐1,3‐dioxolan‐2‐yl)propanoate 
• 4388-57-2 tert-butyldimethylsilyl 3-(2-methyl-1,3-dioxolan-2-yl)propanoate 
• 92404-00-7 Acetic acid 3-(2-methyl-[1,3]dioxolan-2-yl)-propoxymethyl ester 
• 107-21-1 ethylene glycol 
• 941-43-5 Ethyl levulinate ethylene ketal 
• 29021-95-2 1-acetoxy-3-(2-methyl-[1,3]dioxolan-2-yl)-propane 

Downstream Products

• 1374584-68-5 (S,E)-methyl 5-(((benzyloxy)carbonyl)((tert-butyldimethylsilyl)oxy)amino)-7-(2-methyl-1,3-dioxolan-2-yl)hept-2-enoate 
• 930573-19-6 (E)-5-(2-methyl-1,3-dioxolan-2-yl)pent-2-enal 
• 1386999-48-9 (E)-methyl 5-(2-methyl-1,3-dioxolan-2-yl)pent-2-enoate 
• 1243634-57-2 (-)-methyl (1R,2R,3S,5S)-3-(hydroxy)-1,8-dimethyl-8-azabicyclo[3.2.1]octane-2-carboxylate methanesulfonic acid salt 
• 1243634-49-2 (-)-methyl (1S,2R,3R,6S)-3-methyl-7-aza-8-oxatricyclo[4.2.1.0(3,7)]-nonane-2-carboxylate 
• 1243634-48-1 (S,E)-2-(4-methoxy-4-oxobut-2-en-1-yl)-5-methyl-3,4-dihydro-2H-pyrrole 1-oxide. 
• 1243634-58-3 (-)-methyl (1R,2R,3S,5S)-3-(benzoyloxy)-1,8-dimethyl-8-azabicyclo[3.2.1]octane-2-carboxylate 
• 930573-18-5 (E)-5-(2-Methyl-[1,3]dioxolan-2-yl)-pent-2-en-1-ol 
• 3054-93-1 [3-(2-Methyl-[1,3]dioxolan-2-yl)-propylidene]-triphenyl-λ⁵-phosphane 
• 110-93-0 6-Methyl-hept-5-en-2-on 
• 3695-38-3 2-methyl-2-(4-methyl-3-pentenyl)-1,3-dioxolane 
• 87050-28-0 3-acetoxy-6,6-(ethylenedioxy)-2-methyleneheptanoic acid, methyl ester 
• 87050-26-8 6,6-(ethylenedioxy)-3-hydroxy-2-methyleneheptanoic acid, methyl ester 
• 34312-78-2 6,6-(ethylenedioxy)-2-methyl-2-heptenoic acid, methyl ester 

Relevant articles and documents

GGA DERIVATIVES

This invention relates to geranylgeranyl acetone (GGA) derivatives, pharmaceutical compositions comprising GGA derivatives and the use of GGA derivatives.

GGA AND GGA DERIVATIVES COMPOSITIONS THEREOF AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES INCLUDING PARALYSIS INCLUDING THEM

This invention relates to geranylgeranyl acetone (GGA) derivatives and the use of GGA, its isomers, and GGA derivatives in methods for inhibiting neural death, increasing neural activity, increasing axon growth and cell viability, and increasing the survival rate of subjects administered the GGA or GGA derivatives.

METHODS FOR TREATING NEURODEGENERATIVE DISEASES

This invention relates to the 5-cis and 5-trans isomers of geranylgeranyl acetone, preferably such synthetic isomers, and pharmaceutical compositions containing such isomers. Other aspects of this invention relate to the use of geranylgeranyl acetone and its isomers in methods for inhibiting neural death, increasing neural activity, and increasing axon growth and cell viability. Geranylgeranyl acetone is a known anti-ulcer drug used commercially and in clinical situations. GGA has also been shown to exert cytoprotective effects on a variety of organs, such as the eye, brain, and heart.